For nearly 30 years, Gilead has led the development of antiviral therapy especially against AIDS and HIV. The availability of HIV therapies has helped avert an estimated 7.8 million AIDS deaths since 2000. Gilead will soon be launching a number of new products in Switzerland, moving into a new era in this domain.
More than 770,000 hepatitis C patients around the world have initiated treatment with a Gilead product since the company introduced its first treatment in late 2013. Today, Sovaldi® is approved in 65 countries and Harvoni®, the first once-daily STR treatment of chronic hepatitis C virus (HCV) infection in genotype 1 patients, is approved in 50 countries.
Contact
Address: Turmstrasse 28, 6300 Zug, Switzerland
Phone: +41 41 580 02 00
André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s…
Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the…
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high…
Based at Gilead Sciences’ Hong Kong hub, as VP & GM of Asia, Turkey, and the Middle East, American Dustin Haines oversees a vast region that includes the “Asia 5”…
With a welter of regulatory upgrades in the UAE and Saudi Arabia in recent years, patients in the Middle East’s leading countries now have wider and faster access to cutting-edge…
16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East & Russia cluster. He discusses…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
A roundup of recent pharma and healthcare news from Vietnam including Gilead’s viral hepatitis initiative, the country’s explosion of dengue fever cases and the investigation into Boston Scientific’s Vietnam operations.…
A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs,…
See our Cookie Privacy Policy Here
